JPRN-UMIN000019556
Completed
未知
Hormonal therapy resistant estorgen receptor positive metastatic breast cancer cohort study - HORSE-BC
General Incorporated Association of CSPOR-BC0 sites200 target enrollmentNovember 1, 2015
ConditionsBreast cancer
Overview
- Phase
- 未知
- Intervention
- Not specified
- Conditions
- Breast cancer
- Sponsor
- General Incorporated Association of CSPOR-BC
- Enrollment
- 200
- Status
- Completed
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- Not provided
Exclusion Criteria
- •A case that corresponds to any of the following is excluded from participating in this study as a subject. (1\)HER2\-positive breast cancer. (2\)A case not indicated for endocrine therapy. (3\)Any other case that a physician determines to be unsuitable for participation in this study.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Not Applicable
Clinical Trial of a Selective Estrogen Receptor Modulator (raloxifene) in Schizophreniacognitive deficits in patients with schizophreniapsychotic symptoms in patients with schizophreniaMental Health - SchizophreniaACTRN12608000461392niversity of New South Wales80
Not yet recruiting
Phase 3
Letrozole for Estrogen/Progesterone Receptor positive low-grade serous Epithelial ovarian cancer. A randomized phase III trial.
LEPRE Trial2024-516874-31-00Ente Ospedaliero Ospedali Galliera Di Genova132
Recruiting
Not Applicable
Gonadotropin-releasing hormone (GnRH) agonist for prevention of chemotherapy induced menopause in malignant ovarian germ cell tumor: a multicenter studyDiseases of The genitoruinary systemKCT0003286Bundang CHA General Hospital65
Not yet recruiting
Not Applicable
Evaluating utility of Oestrogen and Progesterone Receptor biomarkers for prediction of colorectal CancerCTRI/2024/05/068054Datta Meghe Institute of Higher Education & Research (DMIHER)
Active, not recruiting
Phase 3
Chemotherapy or chemotherapy + hormonotherapy in women over 70 with HER2 receptor-negative but estrogen receptor-positive breast cancer according to their genomic grade2024-516996-34-00Unicancer1,989